Molecular Partners AG
3.33 CHF-0.01 (-0.30%)
ListedCHF125MHealthcareBiotechnology158 employees
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Schlieren, Switzerland, specializing in the development of DARPin therapeutics. DARPins, or Designed Ankyrin Repeat Proteins, represent a novel class of custom-built protein drugs derived from natural binding proteins, offering high specificity, multi-functionality, and multi-target capabilities that surpass limitations of conventional modalities like monoclonal antibodies. The company focuses primarily on oncology, immuno-oncology, ophthalmology, and infectious diseases, with candidates in clinical and preclinical stages, including radio-DARPins, tetra-specific T cell engagers, and switch-DARPins targeting markers such as DLL3, CD33, CD123, CD70, and mesothelin. Molecular Partners AG has established strategic partnerships with major pharmaceutical firms including Allergan, Amgen, Roche, Janssen, and Novartis, fostering co-development of innovative therapies. Employing around 153 professionals, it advances a pipeline addressing unmet medical needs in cancer and serious disorders through its proprietary platform.
Total Cash (MRQ)
78.8M
Total Debt (MRQ)
3.3M
Current Ratio (MRQ)
9.43
Book Value / Share
1.82